DABIGATREX 110 is a prescription oral anticoagulant that contains 110 mg of Dabigatran Etexilate, a proven direct thrombin inhibitor that is used to treat and prevent thromboembolic diseases. In individuals with specific cardiovascular diseases, it is essential for lowering the risk of stroke, systemic embolism, and venous thromboembolism (VTE).

In contrast to conventional anticoagulants, Dabigatran eliminates the requirement for routine blood monitoring in the majority of patients by acting through a focused and predictable mechanism. In India, DABIGATREX 110 is frequently administered to patients in need of more convenient and safe blood thinners.

DABIGATREX 110 has grown to be a significant choice in contemporary cardiology and internal medicine practice due to its dependable clinical profile and user-friendliness.

Uses

DABIGATREX 110 is primarily indicated for the prevention and management of blood clot–related conditions. Common clinical uses include:

• Prevention of Stroke and Systemic Embolism
  In patients with non-valvular atrial fibrillation, DABIGATREX 110 significantly reduces the risk of stroke caused by clot formation.

• Prevention of Deep Vein Thrombosis (DVT)
  Helps prevent clot formation in deep veins, particularly after orthopedic surgeries such as hip or knee replacement.

• Pulmonary Embolism (PE) Prevention and Treatment
  Reduces the risk of clots traveling to the lungs, which can cause life-threatening breathing complications.

• Post-Surgical Thromboprophylaxis
  Used to prevent venous thromboembolism following major surgeries where clot risk is high.

DABIGATREX 110 offers consistent anticoagulation support across both acute and long-term treatment settings.

Benefits

DABIGATREX 110 provides multiple therapeutic and practical benefits for patients and healthcare providers:

1. Direct and Targeted Action

Dabigatran directly inhibits thrombin (Factor IIa), a key enzyme responsible for clot formation. This targeted action ensures effective anticoagulation with predictable outcomes.

2. Reduced Risk of Stroke

In patients with atrial fibrillation, DABIGATREX 110 lowers the risk of ischemic stroke and systemic embolism, improving long-term cardiovascular safety.

3. No Routine INR Monitoring

Unlike warfarin, DABIGATREX 110 does not usually require regular INR testing, offering greater convenience and better patient compliance.

4. Rapid Onset of Action

The medication begins working quickly, making it suitable for situations where immediate anticoagulation is required.

5. Fixed Dosing

Simplified dosing reduces the complexity of treatment and minimizes dosing errors.

6. Improved Quality of Life

With fewer dietary restrictions and less frequent monitoring, patients experience improved comfort and adherence to therapy.

These advantages make DABIGATREX 110 a preferred anticoagulant in many clinical scenarios.

Dosage

The dosage of DABIGATREX 110 must always be determined by a qualified healthcare professional based on the patient’s condition, age, kidney function, and bleeding risk.

• Typical Dose:
  One capsule of DABIGATREX 110 mg, taken once or twice daily as prescribed.

• Administration:
  Capsules should be swallowed whole with water. Do not crush, chew, or open the capsule, as this may increase bleeding risk.

• With or Without Food:
  Can be taken with or without meals, though taking it at the same time daily is recommended.

• Duration of Therapy:
  Treatment duration may vary from short-term (post-surgical use) to long-term (atrial fibrillation or chronic thromboembolic conditions).

Patients should never adjust the dose or discontinue the medication without medical advice, as this can significantly increase the risk of clot formation.

Side Effects

Like all anticoagulants, DABIGATREX 110 may cause side effects, most of which are related to bleeding. However, many patients tolerate the medication well.

Common Side Effects:

• Indigestion or stomach discomfort

• Nausea

• Mild bleeding (nosebleeds, gum bleeding)

• Easy bruising

Less Common but Serious Side Effects:

• Severe or uncontrolled bleeding

• Blood in urine or stools

• Vomiting blood or black stools

• Severe weakness or dizziness

Any signs of excessive bleeding or unusual symptoms should be reported to a doctor immediately. Early medical intervention can prevent serious complications.

Precautions and Warning

Certain precautions must be followed to ensure the safe use of DABIGATREX 110:

1. Kidney Function

Dabigatran is eliminated through the kidneys. Patients with kidney impairment require dose adjustment and close monitoring.

2. Bleeding Risk

Use with caution in patients with bleeding disorders, recent surgery, or a history of gastrointestinal bleeding.

3. Pregnancy and Breastfeeding

DABIGATREX 110 should be used during pregnancy or breastfeeding only if clearly prescribed by a healthcare professional.

4. Drug Interactions

Inform your doctor about all medications, including antiplatelets, NSAIDs, or herbal supplements, as they may increase bleeding risk.

5. Surgical or Dental Procedures

Doctors must be informed before any planned surgery or dental procedure, as temporary discontinuation may be required.

6. Avoid Abrupt Discontinuation

Sudden stoppage can increase the risk of stroke or thrombosis. Any discontinuation should be medically supervised.

Following these precautions ensures maximum safety and therapeutic benefit from DABIGATREX 110.

Conclusion

DABIGATREX 110 is a clinically proven and reliable oral anticoagulant containing Dabigatran Etexilate 110 mg, designed to prevent and manage serious thromboembolic conditions. Its direct mechanism of action, predictable anticoagulation, reduced monitoring requirements, and convenient dosing make it a valuable choice in modern cardiovascular care.